open access

Vol 18, No 2 (2013)
Case reports
Published online: 2013-03-01
Submitted: 2012-04-19
Get Citation

Nasopharyngeal mucoepidermoid carcinoma: A case report and review of literature

Javier Martínez Ollero, Asunción Hervás Morón, Ángel Montero Luis, Soraya Marcos Sánchez, Andrea Abondano Nazarewsky, M José López, Alfredo Ramos Aguerri
DOI: 10.1016/j.rpor.2012.10.002
·
Rep Pract Oncol Radiother 2013;18(2):117-120.

open access

Vol 18, No 2 (2013)
Case reports
Published online: 2013-03-01
Submitted: 2012-04-19

Abstract

Background

Salivary gland-type tumors originating in the nasopharynx are rare, and only a few articles about mucoepidermoid carcinomas (MEC) in this location have been reported. We describe one case of nasopharyngeal MEC and, based on a review of the literature, discuss different therapeutic approaches that can be taken regarding the result of histological findings, radiological tests and extent of disease.

Case presentation

A 47-year-old woman diagnosed with mucoepidermoid carcinoma of nasopharynx, T1 N3 M0 (stage IV-B) was treated in 2007 with a combination of radiotherapy and chemotherapy to a maximum dose of 70[[ce:hsp sp="0.25"/]]Gy and concomitant Cisplatin during the radiation. One year later, with the head and neck disease under control, mediastinal nodes relapse appeared which were treated with exclusive radiotherapy to a maximum dose of 65[[ce:hsp sp="0.25"/]]Gy. One year after the first relapse, a second relapse was detected in the right lung, next to the previously treated mediastinal regions, and the patient initiated a treatment with exclusive chemotherapy based on TPF scheme.

Conclusion

For limited or resectable MEC, combined surgery with radiotherapy, or radiochemotherapy, should be considered the main treatment policy. On the other hand, in poorly differentiated, unresectable tumors or nasopharyngeal MEC, radiochemotherapy could be currently the main treatment approach.

Abstract

Background

Salivary gland-type tumors originating in the nasopharynx are rare, and only a few articles about mucoepidermoid carcinomas (MEC) in this location have been reported. We describe one case of nasopharyngeal MEC and, based on a review of the literature, discuss different therapeutic approaches that can be taken regarding the result of histological findings, radiological tests and extent of disease.

Case presentation

A 47-year-old woman diagnosed with mucoepidermoid carcinoma of nasopharynx, T1 N3 M0 (stage IV-B) was treated in 2007 with a combination of radiotherapy and chemotherapy to a maximum dose of 70[[ce:hsp sp="0.25"/]]Gy and concomitant Cisplatin during the radiation. One year later, with the head and neck disease under control, mediastinal nodes relapse appeared which were treated with exclusive radiotherapy to a maximum dose of 65[[ce:hsp sp="0.25"/]]Gy. One year after the first relapse, a second relapse was detected in the right lung, next to the previously treated mediastinal regions, and the patient initiated a treatment with exclusive chemotherapy based on TPF scheme.

Conclusion

For limited or resectable MEC, combined surgery with radiotherapy, or radiochemotherapy, should be considered the main treatment policy. On the other hand, in poorly differentiated, unresectable tumors or nasopharyngeal MEC, radiochemotherapy could be currently the main treatment approach.

Get Citation

Keywords

Mucoepidermoid carcinoma; Nasopharynx; Salivary gland tumor; Radiotherapy; MEC; Chemotherapy

About this article
Title

Nasopharyngeal mucoepidermoid carcinoma: A case report and review of literature

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 18, No 2 (2013)

Pages

117-120

Published online

2013-03-01

DOI

10.1016/j.rpor.2012.10.002

Bibliographic record

Rep Pract Oncol Radiother 2013;18(2):117-120.

Keywords

Mucoepidermoid carcinoma
Nasopharynx
Salivary gland tumor
Radiotherapy
MEC
Chemotherapy

Authors

Javier Martínez Ollero
Asunción Hervás Morón
Ángel Montero Luis
Soraya Marcos Sánchez
Andrea Abondano Nazarewsky
M José López
Alfredo Ramos Aguerri

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl